On February 22, 2017, Sonex Health announced the successful completion of the first ultrasound-guided carpal tunnel release procedure in the United States using the SX-One MicroKnife™. The SX-One MicroKnife™ is an ultra-low profile surgical device that allows physicians to perform Micro-invasive carpal tunnel release (CTR) surgery through a single micro-incision (4-5 mm) using ultrasound guidance.
The scenario is common. A new medical technology is introduced that potentially improves care and practice economics, but also disrupts conventional care patterns. The question in these scenarios is, “How do we quantify the clinical and economic value and how do we communicate that to clinicians?”
7D Surgical announced today that it has received both 510(k) clearance from the U.S. Food and Drug Administration (FDA) and a medical device license from Health Canada enabling the North American commercial launch of its innovative Machine-vision Image Guided Surgery (MIGS™) system for spine surgery, the 7D Surgical System. This breakthrough system is designed to simplify and speed up surgical workflow, increase surgeon control, eliminate intraoperative radiation, and deliver exceptional value.
DevicePharm is pleased to announce Amber Chao’s promotion to Vice President, Group Account Director at DevicePharm. Amber has lead teams that have helped DevicePharm clients successfully launch dozens of market-leading and innovative brands around the globe. She has earned the respect of both clients and colleagues.
DevicePharm, a marketing strategy and integrated marketing solutions firm, was awarded two 2016 International Davey Awards this month for work created on behalf of Bausch + Lomb’s VICTUS® Femtosecond Laser Platform brand and Clarity Medical’s HOLOS IntraOp™ brand.
DevicePharm co-sponsored, along with Medical Alley Association, an interactive panel titled “Medical Device Marketing Through the Eyes of Your Customers”. The event, held on November 10 at the new U.S. Bank Stadium in Minneapolis, was hosted by DevicePharm CEO, Clay Wilemon, and was an overwhelming success.
DevicePharm, along with six other Orange County professional services firms, co-sponsored the 2016 OCTANe LaunchPad ‘Company Of The Year’ award. The LaunchPad Program gave nine early-stage companies the opportunity to present to a panel of investors with the chance to receive a bundle of professional services ranging from brand development to intellectual property, reimbursement, and financial services.
Big Data. The term is ubiquitous in our culture and its importance was validated by the attendance of over 500 people at the leadoff panel during the OCTANe 2016 Medical Device and Investor Forum. The panel, titled “Using Big Data To Improve Patient Outcomes and Reimbursement” was hosted by DevicePharm CEO, Clay Wilemon.
Every medical marketer wants to know one thing, “What are my customers thinking?”. On November 10, 2016, DevicePharm and Medical Alley will co-host an event designed to answer that very question. Titled ‘Medical Device Marketing Through the Eyes of Your Customers’, this event will feature a panel that includes surgeons, interventionalists, and hospital and practice executives from the Twin Cities area.
Much-anticipated breast cancer results from the prospective, randomized clinical study known as MINDACT were published in the August 24, 2016 edition of the New England Journal of Medicine. The MINDACT study evaluated the MammaPrint® 70-Gene Breast Cancer Recurrence Assay in 6,693 patients to determine its ability to help physicians identify which early-stage breast cancer patients would, and would not, likely benefit from chemotherapy.